Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include ...

In examining recent analyst actions, we gain insights into how financial experts perceive Eli Lilly. The following summary outlines key analysts, their recent evaluations, and adjustments to ...

Best Pharma Stocks to Invest in Now. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) ...

Rather counterintuitively, following some promising news about a pipeline drug, one analyst tracking Eli Lilly (NYSE: LLY) stock cut his price target on the pharmaceutical giant. Even though that ...

LLY has delivered impressive returns of 15% year-to-date (as of April 30), outperforming the S&P 500’s 5% decline during the ...

Now, this won't come as too much of a surprise to Eli Lilly and its peers. A few weeks ago, the company's CEO, David Ricks, ...

Following the sell-off, Lilly trades at a forward price-to-earnings (P/E) of 37 times 2025 analyst estimates, with a price-to ...

Eli Lilly (NYSE:LLY) harnessed significant operational performance during the latest quarter, reporting robust sales and net ...

Indianapolis-based Eli Lilly and Co. on Thursday posted 45% revenue growth in the first quarter of 2025 that topped Wall Street expectations, but stock prices tumbled more than 10% by midday after ...

Indeed, shares of the three biggest pharmaceutical companies based on market cap -- AbbVie (NYSE: ABBV), Eli ... of Lilly's rival weight-loss drug, Zepbound, in July, Evercore ISI analyst Umer ...

While arch rival Eli Lilly and Company ... a step function change for Lilly’s market leadership over NVO and its peers. Lilly management provided insights into the advantages of why the ...

Rather counterintuitively, following some promising news about a pipeline drug, one analyst tracking Eli Lilly (NYSE: LLY) stock cut his price target on the pharmaceutical giant. Even though that ...